Coherus Shelves Eylea Biosimilar And Rules Out Early-Stage Biosimilar Development

Biosimilars Leader Coherus Marks New Era With Immuno-Oncology Play

 
• By Dean Rudge
  
Wooden Blocks Chance Change
Coherus is "still quite open to biosimilar deals" but will will consider them carefully • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business